<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04952519</url>
  </required_header>
  <id_info>
    <org_study_id>00980.045</org_study_id>
    <secondary_id>2021-000981-13</secondary_id>
    <nct_id>NCT04952519</nct_id>
  </id_info>
  <brief_title>Efficacy of Amantadine Treatment in COVID-19 Patients</brief_title>
  <acronym>TITAN</acronym>
  <official_title>Efficacy of Amantadine Treatment in COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noblewell</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Agency (ABM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leszek Giec Upper-Silesian Medical Centre of the Silesian Medical University in Katowice</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Noblewell</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstration of the efficacy of amantadine over placebo in the population of patients with&#xD;
      moderate or severe COVID-19 in the initial stage of the disease treated in the hospital&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Use of high-doses of amantadine in hospitalized patients in the early phase of moderate or&#xD;
      severe COVID-19, compared to placebo, will shorten the duration of the disease and reduce the&#xD;
      risk of death and treatment with invasive mechanical ventilation in Intensive Care Units&#xD;
      (ICU).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to recovery</measure>
    <time_frame>28 days</time_frame>
    <description>Time to recovery, defined as the first day during the 28-day clinical follow-up during which the patient's clinical condition is graded 1, 2, or 3 on an eight-point &quot;Normal Symptom Score&quot;</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Patients With Moderate or Severe COVID-19</condition>
  <arm_group>
    <arm_group_label>Amantadine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amantadine</intervention_name>
    <description>Patients are treated with high doses of amantadine.</description>
    <arm_group_label>Amantadine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age of respondents - 18 years and older.&#xD;
&#xD;
          2. Confirmation of SARS-CoV-2 infection by PCR&#xD;
&#xD;
          3. Hospitalized patient with COVID-19, defined according to the following criteria (all&#xD;
             of the following criteria must be present):&#xD;
&#xD;
               1. radiological (X-ray of klp or TK klp) features of pneumonia,&#xD;
&#xD;
               2. blood saturation (SaO2) measured at rest in the absence of oxygen &lt;95%,&#xD;
&#xD;
               3. it is not necessary to apply on the day of patient enrollment: high-flow oxygen&#xD;
                  therapy or mechanical ventilation (non-invasive or invasive).&#xD;
&#xD;
          4. Time up to 7 days from the onset of COVID-19 symptoms. The onset of COVID-19 symptoms&#xD;
             is the first day on which the first symptom typical for SARS-CoV-2 or COVID-19&#xD;
             infection (in the opinion of the attending physician at the center) occurred, such as:&#xD;
             fever, cough, shortness of breath, changes in taste or smell , muscle pain, chest&#xD;
             pain, diarrhea, nausea, vomiting, sore throat, nasal congestion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or lactation&#xD;
&#xD;
          2. Presence of medical contraindications for inclusion in the examination in the opinion&#xD;
             of the attending physician, in particular:&#xD;
&#xD;
             a) comorbidities: i) clinically significant hepatic or renal insufficiency; ii)&#xD;
             epilepsy or seizures (current or history of); iii) psychiatric or somatic diseases&#xD;
             (present or in a history of agitation or confusion, delirium syndromes or exogenous&#xD;
             psychoses); iv) cardiovascular diseases such as: severe congestive heart failure,&#xD;
             cardiomyopathy, myocarditis, grade II-IV AV block, bradycardia, QT prolongation,&#xD;
             perceived U waves or family history of congenital long QT syndrome, severe ventricular&#xD;
             arrhythmias a history of heart (including torsade de pointes); v) diseases or&#xD;
             conditions that significantly reduce the immunity of a patient (e.g. solid organ&#xD;
             transplant, bone marrow transplantation (BMT), AIDS, immune biologics and / or&#xD;
             high-dose steroids (&gt; 20 mg prednisone daily).&#xD;
&#xD;
             b) hypersensitivity to any component of the preparation, c) parallel use of drugs that&#xD;
             prolong the QT interval, d) hypokalemia or hypomagnesaemia, e) untreated angle-closure&#xD;
             glaucoma, f) use of amantadine currently or in the last 3 months prior to study&#xD;
             inclusion; g) participation in another clinical program&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Barczyk, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Leszek Giec Upper-Silesian Medical Centre of the Silesian Medical University in Katowice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ewa Bachta</last_name>
    <phone>+48323598918</phone>
    <email>ebachta@gcm.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Gronostaj</last_name>
    <phone>+48323598918</phone>
    <email>agronostaj@gcm.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oddział Chorób Płuc i Niewydolności Oddychania z Pododdziałem NWM i Pododdziałem Zaburzeń Oddychania w Czasie Snu, Kujawsko - Pomorskie Centrum Pulmonologii w Bydgoszczy</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Małgorzata Czajkowska-Malinowska, MD</last_name>
    </contact>
    <investigator>
      <last_name>Małgorzata Czajkowska-Malinowska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oddział Pneumonologii Górnośląskie Centrum Medyczne im. prof. Leszka Gieca Śląskiego Uniwersytetu Medycznego w Katowicach</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Barczyk, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Adam Barczyk, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-COV-2</keyword>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amantadine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

